Thread: V81444, Phase 1 / A2A receptor agonist
View Single Post
Old 08-24-2011, 07:14 AM
CarolynS CarolynS is offline
Member
  
Join Date: Nov 2008
Location: Corning NY
Posts: 304
15 yr Member
CarolynS CarolynS is offline
Member
 
Join Date: Nov 2008
Location: Corning NY
Posts: 304
15 yr Member
Default V81444, Phase 1 / A2A receptor agonist
Vernalis Initiates Phase I Trial of V81444 for Parkinson’s Disease

cisionwire, 24 August 2011

Vernalis plc today announces it has dosed the first subjects in a Phase I trial of V81444, its adenosine A receptor antagonist programme. A receptor antagonists are believed to have advantages over conventional dopaminergic strategies, in that they may be able to help restore motor function in patients with Parkinson’s Disease (PD), without the side effects commonly associated with today’s treatments.
CarolynS is offline   Reply With QuoteReply With Quote